AUTHORS
Feiteng Lu, Yuen Lam Dora Ng2, Isay Martinez3, Jan Kroenke, MD4
AFFILIATIONS
1 Charité – Universitätsmedizin Berlin, Berlin, Germany
2 Charité – Universitätsmedizin Berlin, Berlin, Germany
3 Max Delbrück Center for Molecular Medicine, Berlin, Germany
4 Charité – Universitätsmedizin Berlin, Berlin, Germany, Universitätsmedizin Greifswald, Greifswald, Germany
ABSTRACT
Background:
Immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide are cornerstones in the therapy of multiple myeloma (MM). They act as molecular glues that recruit Ikaros transcription factors 1 and 3 (IKZF1/3) to the CRL4CRBN E3 ubiquitin ligase for degradation, thereby suppressing IRF4 and MYC expression and driving myeloma cell death. Despite high initial response rates, most patients ultimately relapse. Known resistance mechanisms include loss or mutation of CRBN and other components of the CRL4 E3 ligase which have been functionally confirmed by genome-wide CRISPR knockout screens. However, these inactivating genetic alterations only account for a minority of resistant patients. Here, we performed genome-wide CRISPR activation screens to identify gain-of-function IMiD resistance genes.
Methods:
We performed genome-wide CRISPR activation (CRISPRa) screen using the Calabrese sgRNA library in MM.1S and OPM2 multiple myeloma cell lines engineered to express dCas9-VP64. Cells were treated with lenalidomide, pomalidomide, mezigdomide or left untreated for 21 days, followed by next-generation sequencing-based quantification of integrated sgRNAs. Enriched and depleted genes were identified using MAGeCK test and MLE algorithms, and screen performance and robustness were confirmed by Gini index-based quality control metrics. Functional validation was performed through stable retroviral overexpression of candidate genes, combined with cell viability and flow cytometry-based competition assays. Domain function was dissected using Defective in Cullin Neddylation 1 Domain Containing 1 (DCUN1D1) UBA- and PONY-domain mutants/truncations in IKZF3-GFP reporter assays. Further mechanistic dissection included immunoblot analysis for IKZF1/3 degradation under IMiD treatment and co-immunoprecipitation to assess CRL4CRBN complex integrity and assembly.
Results:
CRISPRa screening identified robust drug- and cell-line-specific resistance signatures, with genes significantly enriched under IMiD selection in each cell line. Established IMiD pathway components and myeloma driver genes ranked among the top hits in both cell lines, including IKZF1, IKZF3, and IRF4, as well as the recent genes found to cause resistance BATF, BATF2, and POU2AF1, confirming on-target screen fidelity. Cross comparison across both cell lines and all three IMiDs identified only three consistently enriched genes: IKZF3, POU2AF1, and DCUN1D1, which has not been previously reported to be linked to IMiD resistance. DCUN1D1 encodes a neddylation co-E3 ligase for Cullin-RING ligase activity. Analysis of patient datasets revealed that DCUN1D1 is significantly elevated in MM patients compared to healthy donors (GSE6477), and high DCUN1D1 expression in the CoMMpass cohort is associated with inferior progression-free survival and overall survival. Retroviral overexpression of DCUN1D1 in MM.1S and OPM2 cells conferred resistance to all IMiDs but not to other myeloma drugs. Pharmacological inhibition of DCUN1D1 with DI-1859 alone exhibited only modest single-agent activity, but markedly enhanced the anti-myeloma effect of lenalidomide, supporting DCUN1D1 inhibition as a strategy to enhance IMiD sensitivity. Mechanistically, DCUN1D1 overexpression markedly impaired IMiD-induced degradation of IKZF1/3. Domain-mapping showed that the PONY (neddylation) domain was necessary and sufficient to confer resistance. DCUN1D1 overexpression increased cullin neddylation without enhancing global ubiquitination, consistent with dysregulated CRL4-CRBN cycling rather than loss of ligase activity.
Conclusion:
We identify DCUN1D1 as a novel mediator of IMiD resistance in MM via gain-of-function CRISPRa screening. Dysregulated neddylation by DCUN1D1 impairs IKZF1/3 degradation independent of CRBN expression, revealing a previously unrecognized resistance mechanism and positions the DCUN1D1-neddylation axis as a therapeutic candidate in IMiD-refractory myeloma.
DISCLOSURES
Feiteng Lu: No relevant conflicts of interest to declare.